Martek Revenue Could Double, Reach $90 Mil. In FY 2003, CEO Says
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences expects to double its penetration in both domestic and international infant formula markets by next year, company execs said during a June 6 analysts' call
You may also be interested in...
Martek Fiscal 2002 Sales Jump 144.7%; WIC Acceptance Aids Growth
Infant formulas fortified with Martek Biosciences' DHA and ARA fatty acids have been accepted by the WIC program in roughly 15 states, Chief Executive Officer Henry Linsert said in a Dec. 12 analysts call
DHA, ARA Benefit Preterm Infants, Research Shows; Formulas On Horizon
Infant formula fortified with docosahexaenoic acid (DHA) and arachidonic acid (ARA) provide significant growth benefits over non-fortified formula in preterm infants, study results indicate
Mead DHA/ARA-Fortified Infant Formula Slated For February Release
Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said